 Wells Fargo is reiterating its Overweight rating after Kezar Life Sciences Incs NASDAQ: KZR zeto KZR-616 Phase 2 trial in dermatomyositispolymyositis failed to top placebo on the trials primary endpoint of mean total improvement score TIS. The analysts had. 